Abstract
Cancer spread to bone is a significant cause of morbidity in patients with metastatic spread. Metastatic bone disease is also the most common cause of destructive lesions in the adult skeleton. With improvements in adjuvant therapies and a decline in age-standardized cancer mortality, skeletal metastases are increasingly prevalent in advanced spread (1). As such, there will be greater emphasis on the treatment of patients with metastatic spread. Breast, lung, prostate, and kidney are the carcinomas with the greatest propensity for bony metastatic spread. Common anatomic sites of such spread include the axial skeleton (vertebral bodies) and proximal limb girdles (humeri and femora).
Keywords
- Bone Metastasis
- Photodynamic Therapy
- Spinal Metastasis
- Percutaneous Vertebroplasty
- Metastatic Spinal Cord Compression
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult, and the impostors. Spine 1990; 15:1–4.
Choong PF. Cardiopulmonary complications of intramedullary fixation of long bone metastases. Clin Orthop 2003; S245–253.
Ahmed AA, Heller DS. Fatal pulmonary tumour embolism caused by chondroblastic osteosarcoma: report of a case and review of the literature. Arch Pathol Lab Med 1999; 123:437–440.
Peter RE, Schopfer A, Le Coultre B, Hoffmeyer P. Fat embolism and death during prophylactic osteosynthesis of a metastatic femur using an unreamed femoral nail. J Orthop Trauma 1997; 11:233,234.
Ghogawala Z, Mansfield FL, Borges LF. Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression. Spine 2001; 26:818–824.
Wai EK, Finkelstein JA, Tangente RP, et al. Quality of life in surgical treatment of metastatic spine disease. Spine 2003; 28:508–512.
Wedin R, Bauer HC, Rutqvist LE. Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer 2001; 92:257–262.
Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine 2001; 26:298–306.
Hatrick NC, Lucas JD, Timothy AR, Smith MA. The surgical treatment of metastatic disease of the spine. Radiother Oncol 2000; 56:335–339.
Gerszten PC, Welch WC. Current surgical management of metastatic spinal disease. Oncology (Huntingt) 2000; 14:1013–1024; discussion 1024, 102, 1030.
Weigel B, Maghsudi M, Neumann C, Kretschmer R, Muller FJ, Nerlich M. Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine 1999; 24:2240–2246.
Klekamp J, Samii H. Surgical results for spinal metastases. Acta Neurochir (Wien) 1998; 140: 957–967.
Finkelstein J, Zaveri G, Wai E, Vidmar M, Kreder H, Chow E. A population-based study of surgery for spinal metastases: Survival rates and complications. J Bone Joint Surg Br 2003; 85-B:1045–1050.
Amar AP, Larsen DW, Esnaashari N, Albuquerque FC, Lavine SD, Teitelbaum GP. Percutaneous transpedicular polymethylmethacrylate vertebroplasty for the treatment of spinal compression fractures. Neurosurgery 2001; 49:1105–1114; discussion 1114, 1115.
Mathis JM, Barr JD, Belkoff SM, Barr MS, Jensen ME, Deramond H. Percutaneous vertebroplasty: a developing standard of care for vertebral compression fractures. AJNR Am J Neuroradiol 2001; 22:373–381.
Rodriguez-Catarino M. [Percutaneous vertebroplasty—a new method for alleviation of back pain]. Lakartidningen 2002; 99:882–890.
Ratliff J, Nguyen T, Heiss J. Root and spinal cord compression from methylmethacrylate vertebroplasty. Spine 2001; 26:E300–302.
Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60:4066–4069.
Luna MC, Ferrario A, Wong S, Fisher AM, Gomer CJ. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res 2000; 60:1637–1644.
Gomer CJ, Luna M, Ferrario A, Wong S, Fisher AM, Rucker N. Cellular targets and molecular responses associated with photodynamic therapy. J Clin Laser Med Surg 1996; 14:315–321.
Whitacre CM, Feyes DK, Satoh T, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice. Clin Cancer Res 2000; 6:2021–2027.
Whitacre CM, Satoh TH, Xue L, Gordon NH, Oleinick NL. Photodynamic therapy of human breast cancer xenografts lacking caspase-3. Cancer Lett 2002; 179:43–49.
Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999; 137:91–98.
Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumours. Photochem Photobiol 2001; 74:712–720.
Ratkay LG, Chowdhary RK, Iamaroon A, et al. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 1998; 41:525–534.
Xue LY, Chiu SM, Oleinick NL. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene 2001; 20:3420–3427.
Allison R, Mang T, Hewson G, Snider W, Dougherty D. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer 2001; 91:1–8.
Wyss P, Schwarz V, Dobler-Girdziunaite D, et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int J Cancer 2001; 93:720–724.
Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U, Wyss P. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol 2001; 80:62–66.
Sutedja G, Risse R, Van Mourik JC, Postmus PE. Photodynamic therapy for treatment of bronchial carcinomas. Thorax 1994; 49:289,290.
Sutedja TG, Postmus PE. Photodynamic therapy in lung cancer. A review. J Photochem Photobiol B 1996; 36:199–204.
Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E, Kriegmair M. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumours. J Urol 1998; 159: 401–404.
Nseyo UO. Photodynamic therapy in the management of bladder cancer. J Clin Laser Med Surg 1996; 14:271–280.
Walther MM, Delaney TF, Smith PD, et al. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder. Urology 1997; 50:199–206.
Barr H, Dix AJ, Kendall C, Stone N. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. Aliment Pharmacol Ther 2001; 15:311–321.
Nambisan RN, Karakousis CP, Holyoke ED, Dougherty TJ. Intraoperative photodynamic therapy for retroperitoneal sarcomas. Cancer 1988; 61:1248–1252.
Hourigan AJ, Kells AF, Schwartz HS. In vitro photodynamic therapy of musculoskeletal neoplasms. J Orthop Res 1993; 11:633–637.
Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999; 79:1702–1708.
Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH. Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol 1996; 63: 229–237.
Kusuzaki K, Minami G, Takeshita H, et al. Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J Cancer Res 2000; 91:439–445.
Kusuzaki K, Aomori K, Suginoshita T, et al. Total tumour cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas following photodynamic therapy with acridine orange. Oncology 2000; 59: 174–180.
Trauner KB, Gandour-Edwards R, Bamberg M, Shortkroff S, Sledge C, Hasan T. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem Photobiol 1998; 67:133–139.
Beischer AD, Bhathal P, de Steiger R, Penn D, Stylli S. Synovial ablation in a rabbit rheumatoid arthritis model using photodynamic therapy. ANZ J Surg 2002; 72:517–522.
Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99:3083–3088.
Danilatou V, Lydaki E, Dimitriou H, Papazoglou T, Kalmanti M. Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine. Leuk Res 2000; 24:427–435.
Villeneuve L. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem 1999; 30(Pt 1):1–17.
Yamazaki T, Sieber F. Effect of hypothermia on the merocyanine 540-mediated purging of hematopoietic cells. J Hematother 1997; 6:31–39.
Mulroney CM, Gluck S, Ho AD. The use of photodynamic therapy in bone marrow purging. Semin Oncol 1994; 21:24–27.
Sieber F, Gaffney DK, Yamazaki T, Qiu K. Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. Prog Clin Biol Res 1994; 389:147–154.
Koudinova NV, Pinthus JH, Brandis A, et al. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 2003; 104: 782–789.
Firbank M, Hiraoka M, Essenpreis M, Delpy DT. Measurement of the optical properties of the skull in the wavelength range 650-950 nm. Phys Med Biol 1993; 38:503–510.
Takeuchi A, Araki R, Proskurin SG, et al. A new method of bone tissue measurement based upon light scattering. J Bone Miner Res 1997; 12:261–266.
Tauber S, Baumgartner R, Schorn K, Beyer W. Lightdosimetric quantitative analysis of the human petrous bone: experimental study for laser irradiation of the cochlea. Lasers Surg Med 2001; 28:18–26.
Tauber S, Schorn K, Beyer W, Baumgartner R. Transmeatal cochlear laser (TCL) treatment of cochlear dysfunction: a feasibility study for chronic tinnitus. Lasers Med Sci 2003; 18:154–161.
Ugnell AO, Oberg PA. The optical properties of the cochlear bone. Med Eng Phys 1997; 19: 630–636.
Hancox NM. Biology of Bone. Cambridge: Cambridge University Press, 1972.
Bamett AH, Culver JP, Sorensen AG, Dale A, Boas DA. Robust inference of baseline optical properties of the human head with three-dimensional segmentation from magnetic resonance imaging. Appl Opt 2003; 42: 3095–3108.
Wang X, Pang Y, Ku G, Stoica G, Wang LV. Three-dimensional laser-induced photoacoustic tomography of mouse brain with the skin and skull intact. Opt Lett 2003; 28:1739–1741.
Holly LT, Foley KT. Three-dimensional fluoroscopy-guided percutaneous thoracolumbar pedicle screw placement. Technical note. J Neurosurg 2003; 99:324–329.
Krasna MJ, Jiao X, Eslami A, Rutter CM, Levine AM. Thoracoscopic approach for spine deformities. J Am Coll Surg 2003; 197:777–779.
Lieberman IH, Kuzhupilly RR, Reinhardt MK, Davros WJ. Three-dimensional computed tomographic volume rendering techniques in endoscopic thoracoplasty. Spine J 2001; 1:390–394.
Yeung AT, Yeung CA. Advances in endoscopic disc and spine surgery: foraminal approach. Surg Technol Int 2003; 11:253–261.
Hadjipavlou AG, Lander PH, Marchesi D, Katonis PG, Gaitanis IN. Minimally invasive surgery for ablation of osteoid osteoma of the spine. Spine 2003; 28:E472–477.
Fessler RG. Minimally invasive percutaneous posterior lumbar interbody fusion. Neurosurgery 2003; 52:1512.
Deen HG, Fenton DS, Lamer TJ. Minimally invasive procedures for disorders of the lumbar spine. Mayo Clin Proc 2003; 78:1249–1256.
Barr JD, Barr MS, Lemley TJ, McCann RM. Percutaneous vertebroplasty for pain relief and spinal stabilization. Spine 2000; 25:923–928.
Jensen ME, Evans AJ, Mathis JM, Kallmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol 1997; 18:1897–1904.
Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop 2003:S176–186.
Bresler F, Roche O, Chary-Valckenaire I, Blum A, Mole D, Schmitt D. [Femoral head osteonecrosis: original extra-articular cementoplasty technique. A series of 20 cases]. Acta Orthop Belg 1999; 65(Suppl 1): 95,96.
Hodge JC. Cementoplasty and the oncologic population. Singapore Med J 2000; 41:407–409.
Marcy PY, Palussiere J, Descamps B, et al. Percutaneous cementoplasty for pelvic bone metastasis. Support Care Cancer 2000; 8:500–503.
Cantwell CP, Obyrne J, Eustace S. Current trends in treatment of osteoid osteoma with an emphasis on radiofrequency ablation. Eur Radiol 2004; 14:607–617.
Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999; 39:187–197.
El-Abdaimi K, Ste-Marie LG, Papavasiliou V, et al. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumour burden within bone. Int J Oncol 2003; 22:883–890.
Harms JE, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 2003; 20:327–334.
Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75:249–258.
Mundy G. Preclinical models of bone metastases. Semin Oncol 2001; 28:2–8.
Nakata A, Tsujimura T, Sugihara A, et al. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res 1999; 19:4131–4138.
Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001; 16:2027–2034.
Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551–3557.
Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88:2979–2988.
Engebraaten O, Fodstad O. Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats. Int J Cancer 1999; 82:219–225.
Burch S, Bisland SK, Whyne CM, Finkelstein J, Wilson B, Yee A. The novel application of photodynamic therapy for spinal metastases: Evaluation in a preclinical athymic nude rat model. Proceedings: North American Spine Society, Annual Meeting, 2003.
Burch S, Wilson B, Bisland SK, Bogaards A, Whyne CM, Yee A. Percutaneous photodynamic therapy for the treatment of metastatic breast carcinoma to the spine. CBCRA 3rd Scientific Conference Reasons for Hope, 2003.
Ree AH, Tvermyr M, Engebraaten O, et al. Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res 1999; 59:4675–4680.
Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876–6881.
Wetterwald A, van der Pluijm G, Que I, et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 2002; 160:1143–1153.
Wilson BC, Olivo M, Singh G. Subcellular localization of Photofrin and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to photofrin-mediated photodynamic therapy. Photochem Photobiol 1997; 65:166–176.
Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61:4418–4424.
Lilge L, Wilson BC. Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. J Clin Laser Med Surg 1998; 16:81–91.
Lilge L, Portnoy M, Wilson BC. Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer 2000; 83:1110–1117.
Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Nango M, Oku N. Induction of intensive tumour suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer 2003; 97: 2027–2034.
Gluck S, Chadderton A, Ho AD. The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro. Photochem Photobiol 1996; 63:846–853.
Kurohane K, Tominaga A, Sato K, North JR, Namba Y, Oku N. Photodynamic therapy targeted to tumour-induced angiogenic vessels. Cancer Lett 2001; 167:49–56.
Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 1998; 58:5425–5431.
Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina 2002; 22:691–697.
Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42: 547–557.
Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: Results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4. Retina 2002; 22:536–544.
Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report No. 3.Arch Ophthalmol 2002; 120:1443–1454.
Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials— TAP Report no. 5. Arch Ophthalmol 2002; 120:1307–1314.
Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002; 22:391–405; quiz 527,528.
Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 2001; 36:332–338.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Burch, S., Yee, A.J.M. (2005). Role of Photodynamic Therapy for Bone Metastasis. In: Singh, G., Rabbani, S.A. (eds) Bone Metastasis. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-892-7:243
Download citation
DOI: https://doi.org/10.1385/1-59259-892-7:243
Publisher Name: Humana Press
Print ISBN: 978-1-58829-403-6
Online ISBN: 978-1-59259-892-2
eBook Packages: MedicineMedicine (R0)